Results 1 to 10 of about 126 (116)

Фармакоэкономический анализ применения гилтеритиниба в лечении взрослых пациентов с рецидивами и рефрактерным течением острых миелоидных лейкозов с мутацией гена FLT3

Клиническая онкогематология, 2022
Актуальность. Появление в клинической практике FLT3-таргетных лекарственных средств (ЛС) изменило подходы к ведению пациентов с острыми миелоидными лейкозами (ОМЛ) с FLT3-мутацией. Одним из них является гилтеритиниб, одобренный FDA в 2018 г.
А. С. Колбин, Юлия Михайловна Гомон, Ю. Е. Балыкина, М. А. Проскурин   +3 more
doaj   +1 more source

Clinical and economic justification of screening for mucopolysaccharidosis type I in children at groups of risks

Качественная клиническая практика, 2021
Background. Mucopolysaccharidosis Type I (MPS I) has clinical heterogeneity without specific symptoms leading to difficulties with diagnostic on time. In-depth screening for MPS I in children has aim of early detection and timely treatment with an enzyme
I. S. Krysanov, V. S. Krysanova, V. Yu. Ermakova   +2 more
doaj   +1 more source

Pharmacoeconomic evaluation of ipragliflozin in combination with metformin in comparison with other regimens of therapy for type 2 diabetes mellitus

Качественная клиническая практика, 2021
Ipragliflozin is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduce plasma glucose concentrations by inhibiting glucose reabsorption by the kidney through inhibiting SGLT2 sodium-glucose cotransporter and induce glycosuria.
A. S. Kolbin, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin   +3 more
doaj   +1 more source

ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

Рациональная фармакотерапия в кардиологии, 2015
Atrial fibrillation (AF) is a risk factor for thromboembolic complications, requiring administration of vitamin K antagonists (warfarin) or the new oral anticoagulants (apixaban, dabigatran and rivaroxaban).Aim. To assess the influence of apixaban use on
A. V. Rudakova
doaj   +1 more source

Clinical and economic analysis of macrocyclic gadolinium-based compounds for use in magnetic resonance imaging diagnostics

Качественная клиническая практика, 2020
Gadolinium-based contrast compounds are paramagnetic chemicals that allow enhancing contrast during magnetic resonance imaging (MRI) tomographic investigation. It`s known that linear gadolinium-based paramagnetic compounds cause permanent accumulation of
A. E. Cheberda, D. U. Belousov
doaj   +1 more source

Pharmacoeconomic feasibility of using Mirabegron in patients with overactive bladder

Качественная клиническая практика, 2021
Objective: to assess the clinical and economic efficiency and impact on the budget when using the drug Mirabegron in the treatment of an overactive bladder. Materials and methods. Study design — retrospective analysis of published data.
I. N. Dyakov, G. R. Kasyan
doaj   +1 more source

An update of pharmacoeconomic analysis of trastuzumab emtanzine in patients with HER2+ breast cancer and central nervous system metastases

Качественная клиническая практика, 2019
Introduction. Regardless the pharmacoeconomic evaluation of trastuzumab emtanzine (T-DM-1) has been done before new data concerning T-DM1 effectiveness and also costs data require an update of pharmacoeconomic evaluation. Aim.
A. S. Kolbin, A. A. Kurylev, Y. E. Balykina, M. A. Proskurin   +3 more
doaj   +1 more source

Pharmacoeconomic analysis of thrombopoietin receptor agonists in the treatment of chronic idiopathic thrombocytopenic purpura in adults

Качественная клиническая практика, 2018
Actuallity. Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disease caused by the production of antibodies to the platelet and megakaryocytes membrane structure, which causes to increase the platelet destruction, but also inadequate ...
E. A. Pyadushkina, M. Yu. Frolov, V. A. Shuvaev, V. A. Rogov   +3 more
doaj   +1 more source

harmacoeconomic feasibility of using the drug upadacitinib in patients with rheumatoid arthritis in the healthcare system of the Russian Federation

Качественная клиническая практика, 2020
Aim. To assess the pharmacoeconomic feasibility of including the drug upadacitinib in restrictive lists and government funding programs to provide patients with rheumatoid arthritis.Materials and methods.
A. M. Lila, S. K. Zyryanov, I. N. Dyakov
doaj   +1 more source

Pharmacoeconomic evaluation of the ceftolosan + tasobactam in the treatment of complicated nosocomial intraabdominal infections

Качественная клиническая практика, 2019
Objective. To perform the pharmacoeconomic analysis of ceftolosan + tazobactam (Zerbaxa®) compared with the routine practice of antibacterial therapy of complicated intra-abdominal infections (clAI) and ceftazidime + avibactam (Zavicefta®).Methods.
I. N. Dyakov, S. K. Zyryanov, N. N. Khachatryan   +2 more
doaj   +1 more source